Featured

Genentech (Roche) has announced a voluntarily manufacturing recall for their implant (Port Delivery System with ranibizumab, “Susvimo”) to treat neovascular age-related macular degeneration (nAMD)

Genentech (Roche) has announced a voluntarily recall of the “Susvimo” (ranibizumab injection) ocular implant for wet AMD, citing a manufacturing problem with the device. The… Read More »Genentech (Roche) has announced a voluntarily manufacturing recall for their implant (Port Delivery System with ranibizumab, “Susvimo”) to treat neovascular age-related macular degeneration (nAMD)

Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.

Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.

Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10

Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10